Tiziana Life Sciences (TLSA) Other Non-Current Liabilities (2019 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Other Non-Current Liabilities of $9000.0 for Q2 2025, up 12.5% year-on-year from $8000.0 in Q2 2024, and down 25.0% on a QoQ basis from $12000.0 in Q4 2024.
Tiziana Life Sciences (TLSA) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Tiziana Life Sciences (TLSA) has reported Other Non-Current Liabilities for 7 consecutive years, with $9000.0 the latest figure, recorded in Q2 2025.
- Quarterly Other Non-Current Liabilities rose 12.5% year-over-year to $9000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $9000.0 (up 12.5% YoY) and the FY2024 annual result came in at $12000.0, down 14.29% from the prior year.
- Other Non-Current Liabilities fell to $9000.0 in Q2 2025 per TLSA's latest filing, from $12000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for TLSA reached as high as $365000.0 in Q4 2022 and fell as low as $6000.0 in Q2 2023.
- A 5-year average of $57222.2 and a median of $10000.0 in 2021 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 3550.0% — and 2023, when it sank 96.16%.
- Year by year, Other Non-Current Liabilities stood at $10000.0 in 2021, then soared by 3550.0% to $365000.0 in 2022, then plunged by 96.16% to $14000.0 in 2023, then declined by 14.29% to $12000.0 in 2024, then dropped by 25.0% to $9000.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $9000.0, $12000.0, and $8000.0 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Tiziana Life Sciences | 109.20 Mn | 105.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 9,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Dec 31, 2022 | 365,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Jun 30, 2021 | 83,000.00 |
| Dec 31, 2020 | 81,867.96 |
| Dec 31, 2019 | 81,000.67 |